G Tirabassi1, N delli Muti, A Gioia, A Biagioli, A Lenzi, G Balercia. 1. Division of Endocrinology, Department of Clinical and Molecular Sciences, Umberto I Hospital, Polytechnic University of Marche, Via Conca 71, 60126, Ancona, Italy.
Abstract
INTRODUCTION AND AIM: The relationship between androgen receptor (AR) CAG polymorphism and bone metabolism is highly controversial. We, therefore, aimed to evaluate the independent role of AR CAG repeat polymorphism on bone metabolism improvement induced by testosterone replacement therapy (TRT) in male post-surgical hypogonadotropic hypogonadism, a condition frequently associated with hypopituitarism and in which the effects of TRT have to be distinguished from those resulting from concomitant administration of pituitary function replacing hormones. METHODS: 12 men affected by post-surgical hypogonadotropic hypogonadism [mean duration of hypogonadism 8.3 ± 2.05 (SD) months] were retrospectively assessed before and after TRT (from 74 to 84 weeks after the beginning of therapy). The following measures were studied: parameters of bone metabolism [serum markers and bone mineral density (BMD)], pituitary dependent hormones and genetic analysis (AR CAG repeat number). RESULTS: Total testosterone, estradiol, free T4 (FT4) and insulin-like growth factor-1 (IGF-1) increased between the two phases, while follicle stimulating hormone (FSH) decreased. While serum markers did not vary significantly between the two phases, BMD improved slightly but significantly in all the studied sites. The number of CAG triplets correlated negatively and significantly with all the variations (Δ-) of BMDs. Conversely, Δ-testosterone correlated positively and significantly with all studied Δ-BMDs, while Δ-FSH, Δ-estradiol, Δ-FT4, and Δ-IGF-1 did not correlate significantly with any of the Δ-BMDs. Multiple linear regression analysis, after correction for Δ-testosterone, showed that CAG repeat length was negatively and significantly associated with ∆-BMD of all measured sites. CONCLUSIONS: Our data suggest that, in post-surgical male hypogonadotropic hypogonadism, shorter AR CAG tract is independently associated with greater TRT-induced improvement of BMD.
INTRODUCTION AND AIM: The relationship between androgen receptor (AR) CAG polymorphism and bone metabolism is highly controversial. We, therefore, aimed to evaluate the independent role of AR CAG repeat polymorphism on bone metabolism improvement induced by testosterone replacement therapy (TRT) in male post-surgical hypogonadotropic hypogonadism, a condition frequently associated with hypopituitarism and in which the effects of TRT have to be distinguished from those resulting from concomitant administration of pituitary function replacing hormones. METHODS: 12 men affected by post-surgical hypogonadotropic hypogonadism [mean duration of hypogonadism 8.3 ± 2.05 (SD) months] were retrospectively assessed before and after TRT (from 74 to 84 weeks after the beginning of therapy). The following measures were studied: parameters of bone metabolism [serum markers and bone mineral density (BMD)], pituitary dependent hormones and genetic analysis (AR CAG repeat number). RESULTS: Total testosterone, estradiol, free T4 (FT4) and insulin-like growth factor-1 (IGF-1) increased between the two phases, while follicle stimulating hormone (FSH) decreased. While serum markers did not vary significantly between the two phases, BMD improved slightly but significantly in all the studied sites. The number of CAG triplets correlated negatively and significantly with all the variations (Δ-) of BMDs. Conversely, Δ-testosterone correlated positively and significantly with all studied Δ-BMDs, while Δ-FSH, Δ-estradiol, Δ-FT4, and Δ-IGF-1 did not correlate significantly with any of the Δ-BMDs. Multiple linear regression analysis, after correction for Δ-testosterone, showed that CAG repeat length was negatively and significantly associated with ∆-BMD of all measured sites. CONCLUSIONS: Our data suggest that, in post-surgical male hypogonadotropic hypogonadism, shorter AR CAG tract is independently associated with greater TRT-induced improvement of BMD.
Authors: P J Snyder; H Peachey; P Hannoush; J A Berlin; L Loh; J H Holmes; A Dlewati; J Staley; J Santanna; S C Kapoor; M F Attie; J G Haddad; B L Strom Journal: J Clin Endocrinol Metab Date: 1999-06 Impact factor: 5.958
Authors: Amelia Guadalupe-Grau; Francisco Germán Rodríguez-González; Jesús Gustavo Ponce-González; Cecilia Dorado; Hugo Olmedillas; Teresa Fuentes; Jorge Pérez-Gómez; Joaquín Sanchís-Moysi; Bonifacio Nicolás Díaz-Chico; José A L Calbet Journal: PLoS One Date: 2010-07-12 Impact factor: 3.240
Authors: Kristian Løvås; Clara G Gjesdal; Monika Christensen; Anette B Wolff; Bjørg Almås; Johan Svartberg; Kristian J Fougner; Unni Syversen; Jens Bollerslev; Jan A Falch; Penelope J Hunt; V Krishna K Chatterjee; Eystein S Husebye Journal: Eur J Endocrinol Date: 2009-03-12 Impact factor: 6.664
Authors: Farid Saad; Antonio Aversa; Andrea M Isidori; Livia Zafalon; Michael Zitzmann; Louis Gooren Journal: Eur J Endocrinol Date: 2011-07-13 Impact factor: 6.664
Authors: G Rastrelli; L Giovannini; A E Calogero; D Gianfrilli; E Serra; A Pizzocaro; V A Giagulli; G Motta; G Vancieri; A Sperandio; S Andò; R Selice; G Luca; F Cocchiara; D Canale; M Maggi Journal: J Endocrinol Invest Date: 2016-04-01 Impact factor: 4.256
Authors: A M Isidori; G Balercia; A E Calogero; G Corona; A Ferlin; S Francavilla; D Santi; M Maggi Journal: J Endocrinol Invest Date: 2014-11-11 Impact factor: 4.256